BR112022004221A2 - Tratamento de hidradenite com inibidores de jak - Google Patents

Tratamento de hidradenite com inibidores de jak

Info

Publication number
BR112022004221A2
BR112022004221A2 BR112022004221A BR112022004221A BR112022004221A2 BR 112022004221 A2 BR112022004221 A2 BR 112022004221A2 BR 112022004221 A BR112022004221 A BR 112022004221A BR 112022004221 A BR112022004221 A BR 112022004221A BR 112022004221 A2 BR112022004221 A2 BR 112022004221A2
Authority
BR
Brazil
Prior art keywords
treatment
hidradenitis
jak inhibitors
jak
inhibitors
Prior art date
Application number
BR112022004221A
Other languages
English (en)
Inventor
Andrew Fensome
Stephen Gerstenberger Brian
Rhys Owen Dafydd
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112022004221A2 publication Critical patent/BR112022004221A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

tratamento de hidratante com inibidores de jack. a presente invenção refere-se a métodos para o tratamento de hidradenite supurativa usando compostos e análogos que inibem certas quinases, incluindo janus quinase (jak).
BR112022004221A 2019-09-11 2020-09-08 Tratamento de hidradenite com inibidores de jak BR112022004221A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962899133P 2019-09-11 2019-09-11
PCT/IB2020/058333 WO2021048736A1 (en) 2019-09-11 2020-09-08 Treatment of hidradenitis with jak inhibitors

Publications (1)

Publication Number Publication Date
BR112022004221A2 true BR112022004221A2 (pt) 2022-05-31

Family

ID=72473596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004221A BR112022004221A2 (pt) 2019-09-11 2020-09-08 Tratamento de hidradenite com inibidores de jak

Country Status (12)

Country Link
EP (1) EP4028007A1 (pt)
JP (1) JP2021042204A (pt)
KR (1) KR20220059519A (pt)
CN (1) CN114667148A (pt)
AR (1) AR119942A1 (pt)
AU (1) AU2020347561A1 (pt)
BR (1) BR112022004221A2 (pt)
CA (1) CA3153676A1 (pt)
IL (1) IL291146A (pt)
MX (1) MX2022002995A (pt)
TW (1) TW202123940A (pt)
WO (1) WO2021048736A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023178001A1 (en) * 2022-03-17 2023-09-21 Pfizer Inc. Methods, dosage regimens, and compositions for treating hidradenitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151764A1 (es) 2013-02-22 2015-12-03 Pfizer Derivados de pirrolo[2,3-d]pirimidina
NO2721710T3 (pt) * 2014-08-21 2018-03-31
JP7096592B2 (ja) * 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
DK3419978T3 (da) * 2016-02-24 2020-06-02 Pfizer Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
US10323036B2 (en) * 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EA202092343A1 (ru) * 2018-03-30 2021-01-20 Инсайт Корпорейшн Лечение гнойного гидраденита с использованием ингибиторов jak
EP3775284A1 (en) * 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease

Also Published As

Publication number Publication date
WO2021048736A1 (en) 2021-03-18
EP4028007A1 (en) 2022-07-20
AR119942A1 (es) 2022-01-19
CA3153676A1 (en) 2021-03-18
IL291146A (en) 2022-05-01
MX2022002995A (es) 2022-06-02
AU2020347561A1 (en) 2022-04-14
CN114667148A (zh) 2022-06-24
JP2021042204A (ja) 2021-03-18
KR20220059519A (ko) 2022-05-10
TW202123940A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
PH12018501268A1 (en) Compounds useful as kinase inhibitors
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112018069515A2 (pt) uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
BR112018007604A2 (pt) métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112018075201A2 (pt) moduladores do receptor beta-3 adrenérgico úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
WO2018039475A8 (en) Use of pridopidine for treating dystonias
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
BR112017025263A2 (pt) método para o tratamento de doença neurológica
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112021023796A2 (pt) Inibidores de moléculas pequenas de quinase indutora de nf-capab